Seyyed Hossein Khatami1, Mortaza Taheri-Anganeh2, Ahmad Movahedpour3,4, Amir Savardashtaki3,5, Amin Ramezani3,6, Bahador Sarkari7,8, Zohreh Mostafavi-Pour1,9. 1. Recombinant Proteins Laboratory, Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences , Shiraz, Iran. 2. Cellular and Molecular Research Center, Research Institute on Cellular and Molecular Medicine, Urmia University of Medical Sciences , Urmia, Iran. 3. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences , Shiraz, Iran. 4. Student Research Committee, Shiraz University of Medical Sciences , Shiraz, Iran. 5. Epilepsy Research Center, Shiraz University of Medical Sciences , Shiraz, Iran. 6. Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences , Shiraz, Iran. 7. Department of Parasitology and Mycology School of Medicine, Shiraz University of Medical Sciences , Shiraz, Iran. 8. Basic Sciences in Infectious Diseases Research Center, School of Medicine, Shiraz University of Medical Sciences , Shiraz, Iran. 9. Maternal-Fetal Medicine Research Center, School of Medicine, Shiraz University of Medical Sciences , Shiraz, Iran.
Abstract
BACKGROUND: Cystic echinococcosis (CE) is a widespread parasitic disease caused by the larval stage of Echinococcus granulosus. Since current methods for the diagnosis of CE are not efficient enough, rapid, and reliable tests are required for the acceleration of CE diagnosis. The present study aimed to produce recombinant B8/1 and B8/2 antigens of E. granulosus and evaluate their sensitivities and specificities separately and simultaneously for the diagnosis of CE. METHODS: The recombinant B8/1 and B8/2 antigens were produced and used in an ELISA system for the diagnosis of CE. The sera specimens including 30 sera from pathologically confirmed CE patients, 30 from other non-CE patients, and 30 from healthy controls, were evaluated by the ELISA, using AgB8/1 and AgB8/2. RESULTS: The results showed a sensitivity of 93.33%, 90%, and 96.7% for AgB8/1, AgB8/2, and their combination, respectively. The specificities were 91.7%, 93.33%, and 93.33% for AgB8/1, AgB8/2, and their combination, respectively. CONCLUSION: Simultaneous usage of AgB8/1 and AgB8/2 increased the test sensitivity for the diagnosis of CE. Furthermore, the specificity of AgB8/1 and AgB8/2 combination was more than AgB8/1 and equal to AgB8/2 alone. The findings revealed that the simultaneous usage of AgB8/1 and AgB8/2 could be a suitable approach for the diagnosis of CE.
BACKGROUND:Cystic echinococcosis (CE) is a widespread parasitic disease caused by the larval stage of Echinococcus granulosus. Since current methods for the diagnosis of CE are not efficient enough, rapid, and reliable tests are required for the acceleration of CE diagnosis. The present study aimed to produce recombinant B8/1 and B8/2 antigens of E. granulosus and evaluate their sensitivities and specificities separately and simultaneously for the diagnosis of CE. METHODS: The recombinant B8/1 and B8/2 antigens were produced and used in an ELISA system for the diagnosis of CE. The sera specimens including 30 sera from pathologically confirmed CE patients, 30 from other non-CE patients, and 30 from healthy controls, were evaluated by the ELISA, using AgB8/1 and AgB8/2. RESULTS: The results showed a sensitivity of 93.33%, 90%, and 96.7% for AgB8/1, AgB8/2, and their combination, respectively. The specificities were 91.7%, 93.33%, and 93.33% for AgB8/1, AgB8/2, and their combination, respectively. CONCLUSION: Simultaneous usage of AgB8/1 and AgB8/2 increased the test sensitivity for the diagnosis of CE. Furthermore, the specificity of AgB8/1 and AgB8/2 combination was more than AgB8/1 and equal to AgB8/2 alone. The findings revealed that the simultaneous usage of AgB8/1 and AgB8/2 could be a suitable approach for the diagnosis of CE.
Entities:
Keywords:
Diagnosis; cystic echinococcosis; recombinant antigen B
Authors: Ali Reza Safarpour; Mostafa Omidian; Ali Pouryousef; Mohammad Reza Fattahi; Bahador Sarkari Journal: Biomed Res Int Date: 2022-09-05 Impact factor: 3.246